ClinicalTrials.gg
Not yet recruitingNCT07848906Updated Sep 30, 2026

Alcohol and Cancer Message Testing Experiment

An interventional study of Alcohol health harm message exposure in Alcohol, Message Perception and PME, sponsored by University of Connecticut. Not yet recruiting. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Connecticut · Not applicable, Interventional, and Prevention

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

Alcohol increases the risk for at least seven cancers, yet recent estimates suggest only between one-third and one-half of US adults are aware of this risk. The current study aims to develop and test alcohol-cancer messages designed for a mass media public health campaign. The messages will be informed by theory-based constructs proximal to health behavior change (e.g., perceived likelihood/severity of harm, response efficacy). We will evaluate messages via an online, cross-sectional message testing randomized experiment. Participants will be US adults aged 21+ recruited from Qualtrics Panels.

Read the detailed description

Rational:

Alcohol increases the risk for at least seven cancers, yet recent estimates suggest only between one-third and one-half of US adults are aware of this risk. Raising public awareness of the alcohol-cancer link can encourage better informed choices about alcohol and promote reduced consumption, yet the most effective strategies for raising such awareness remain to be determined.

One potential strategy is the use of alcohol-cancer risk messages, which could be disseminated through various communication channels (e.g., public service announcements, communication campaigns). However, such messages can differ in numerous ways, including their substantive content and the specific language used to communicate risk, and the optimal design of these messages and their effects on audiences remains to be determined.

Ours and others' prior work has tested different alcohol-cancer warning label messages in experimental studies. These experiments have tested the effects of using causal vs. hedging language, the utility of adding pictograms in warning labels, different ways to frame the alcohol-cancer risk relationship, and the type of cancer to communicate in warning labels. The overarching goal of these studies was to develop effective warning labels that could be added to alcohol beverages.

The current study aims to extend this work by developing and preliminarily evaluating alcohol-cancer messages designed for a mass media public health campaign. These messages will be informed by theory-based constructs proximal to health behavior change (e.g., perceived likelihood/severity of harm, response efficacy). We will evaluate messages via an online, cross-sectional message testing randomized experiment. Participants will be US adults aged 21+ recruited from Qualtrics Panels.

Objective:

The primary objective of this study is to identify how different alcohol-cancer message frames affect message-related perceptions and related health outcomes (e.g., perceived message effectiveness, risk beliefs, drinking intentions). Findings will help inform future alcohol harm reduction health communication efforts.

Guiding research question:

  1. Do different alcohol-cancer message frames affect people's a) message receptivity, b) alcohol-related attitudes and risk perceptions, and c) drinking intentions?
  2. Do any factors moderate the effects of exposure to different alcohol-cancer message frames (e.g., drinking status as a moderator)?
02

Conditions studied

  • Alcohol
  • Message Perception
  • PME

Browse trials for

Keywords

  • Message testing experiment
  • Alcohol risk messages
  • Alcohol and cancer
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 1,400 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Connecticut is the lead sponsor of 136 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • currently reside in the US;
  • be aged 21 years or older; and
  • speak English.

Exclusion criteria

Exclusion Criteria:

- none beyond failure to meet the inclusion criteria.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,400 participants (estimated)

Study arms

  • Experimental
    Perceived likelihood frame

    Exposure to two alcohol-cancer messages that convey the probability of experiencing a health harm (i.e., cancer) from a particular hazard (i.e., drinking alcohol). The intervention will be administered in an online survey experiment as static images displayed to participants.

    Behavioral: Alcohol health harm message exposure

  • Experimental
    Harm reduction frame

    Exposure to two alcohol-cancer messages that encourage reducing how much alcohol people drink. The intervention will be administered in an online survey experiment as static images displayed to participants.

    Behavioral: Alcohol health harm message exposure

  • Experimental
    Perceived severity frame

    Exposure to two alcohol-cancer messages that convey how serious getting alcohol-associated cancer will be. The intervention will be administered in an online survey experiment as static images displayed to participants.

    Behavioral: Alcohol health harm message exposure

  • Experimental
    Response efficacy frame

    Exposure to two alcohol-cancer messages that emphasize the effectiveness of protective behaviors for reducing alcohol-associated cancer risk. The intervention will be administered in an online survey experiment as static images displayed to participants.

    Behavioral: Alcohol health harm message exposure

  • Experimental
    Harm prevention frame

    Exposure to two alcohol-cancer messages that emphasize completely abstaining from drinking alcohol. The intervention will be administered in an online survey experiment as static images displayed to participants.

    Behavioral: Alcohol health harm message exposure

  • Active comparator
    Surgeon General's frame

    Exposure to two alcohol-cancer messages that do not discuss alcohol-associated cancer risk. Instead, the messages use language from the existing U.S. Surgeon General's warning on alcoholic beverages. The intervention will be administered in an online survey experiment as static images displayed to participants.

    Behavioral: Alcohol health harm message exposure

  • No intervention
    Control

    Participants randomized to control will not be exposed to any message stimuli.

Interventions

  • BehavioralAlcohol health harm message exposure

    Randomized exposure to one of five alcohol-cancer health campaign message frames, or a non-cancer alcohol harms frame.

06

What researchers measure

Primary outcomes

  1. Perceived message effectiveness - effects perceptions

    A 3-item scale adapted from prior effects perception PME and substance use literature. After each message exposure, participants will be asked to respond to the following items: 1) This message discourages me from wanting to drink alcohol; 2) This message makes me concerned about the health effects of drinking alcohol; and 3) This message makes drinking alcohol seem unpleasant to me. Items will be assessed on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). We will assess internal consistency using Cronbach's alpha. Assuming adequate measure reliability, we will average the items into a single composite PME measure.

    Time frame: Day 1; post intervention exposure

Secondary outcomes

  1. Drinking intentions

    Intentions will be assessed with a 3-item scale adapted from prior substance use and health communication research. Participants will answer each of the following questions: How likely is it that you will drink alcohol in the... 1) next week, 2) next month, and 3) next year. Responses will be on 5-point scales ranging from "not at all" (1) to "extremely" (5). We will assess internal consistency using Cronbach's alpha. Assuming adequate measure reliability, we will average the items into a single composite measure.

    Time frame: Day 1; post intervention exposure

  2. Message reactance

    Message reactance will be assessed with a brief 3-item scale used in prior research. Participants will respond to the following statements: 1) This message is trying to manipulate me, 2) The health effect in this message is overblown, and 3) This message annoys me. Responses will be assessed on 5-point scales ranging from "strongly disagree" (1) to "strongly agree" (5). We will assess internal consistency using Cronbach's alpha. Assuming adequate measure reliability, we will average the items into a single composite measure.

    Time frame: Day 1; post intervention exposure

  3. Non-alcoholic beer message perceptions

    A single item that has participants respond to the following statement: "This message makes me think drinking non-alcoholic beer is healthier than alcoholic beer." This item will be assessed on a 5-point scale ranging from strongly disagree (1) to strongly agree (5).

    Time frame: Day 1; post intervention exposure

  4. Perceived message effectiveness - message perceptions

    A 5-item scale assessing perceptions of each message, adapted from prior work. After each message exposure, participants will respond to the following items: 1) "This message grabs my attention"; 2) "This message is believable"; 3) "This message is credible"; 4) "This message is trustworthy"; and 5) "I learned something new from this message." Items will be assessed on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). We will assess internal consistency using Cronbach's alpha. Assuming adequate measure reliability, we will average the items into a single composite measure.

    Time frame: Day 1; post intervention exposure

  5. Attitudes toward alcohol

    A 3-item measure assessing attitudes toward drinking alcohol. Participants will rate drinking alcohol on three 5-point bipolar scales: 1) harmful/safe; 2) bad/good; and 3) unhealthy/healthy. We will assess internal consistency using Cronbach's alpha. Assuming adequate reliability, we will average the items into a single composite attitude measure.

    Time frame: Day 1; post intervention exposure

  6. Intentions to reduce alcohol use

    Assessed only among participants who currently drink alcohol. Participants will be asked, "How likely are you to reduce how much alcohol you drink?" Responses will be assessed on a 5-point scale ranging from not at all (1) to very much (5).

    Time frame: Day 1; post intervention exposure

  7. Alcohol-cancer causal beliefs

    Causal beliefs will be assessed with a single item: "How likely do you think it is that alcohol causes cancer?" Responses will be assessed on a 5-point scale ranging from not at all (1) to very much (5).

    Time frame: Day 1; post intervention exposure

  8. Intentions to quit drinking alcohol

    Participants who currently drink alcohol will be asked, "How likely are you to quit drinking alcohol?" Responses will be assessed on a 5-point scale ranging from not at all (1) to very much (5).

    Time frame: Day 1; post intervention exposure

  9. Alcohol-cancer risk beliefs

    We will assess risk beliefs using a 3-item scale assessing affective, experiential, and deliberative perceptions of cancer risk among participants who currently drink alcohol. The measure stem will state, "If you continue to drink alcohol at your current level…" Participants will then answer the following items: 1) "How worried are you about eventually getting cancer?"; 2) "To what extent could you see yourself eventually getting cancer?"; and 3) "How likely do you think it is that you will eventually get cancer?" Items will be assessed on a 5-point scale ranging from not at all (1) to very much (5). We will assess these items separately, as they tap into different tri-risk constructs; however, for exploratory purposes we will also assess internal consistency of the three items using Cronbach's alpha. Assuming adequate reliability, we will average the items into a single composite measure.

    Time frame: Day 1; post intervention exposure

  10. Support for message on alcohol containers

    Assessed with a single item: "I believe a message like this should be added to alcohol beverage containers." Responses will be assessed on a 5-point scale ranging from strongly disagree (1) to strongly agree (5).

    Time frame: Day 1; post intervention exposure

  11. Perceived effectiveness of message on alcohol containers

    Assessed with a single item: "Seeing a message like this on an alcoholic beverage would make me think twice about drinking alcohol." Responses will be assessed on a 5-point scale ranging from strongly disagree (1) to strongly agree (5).

    Time frame: Day 1; post intervention exposure

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share anonymized IPD with researchers upon reasonable request to the project Principal Investigator.

Time frame: IPD will be available on an ad hoc basis upon reasonable request for at least three years after the experiment is completed.

Access criteria: Other researchers who provide a reasonable request about how they will use the data (e.g., validation, secondary analyses, etc).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2026, 1 month later.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 1 month is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848906
Responsible party
Jacob Rohde (Assistant Professor, University of Connecticut) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Jacob A Rohde, PhD, MPH
Contact
jacob.rohde@uconn.edu
(860) 486-2834

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion